Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

TSX:ATZ
TSX:ATZSpecialty Retail

Aritzia (TSX:ATZ) Same Store Sales Surge Tests Bulls’ Expansion Narrative

Aritzia (TSX:ATZ) has put up another busy quarter, with Q3 2026 revenue of about C$1.0b and basic EPS of C$1.20, alongside net income of C$138.9 million and same store sales growth of 34.3%. The company has seen revenue move from C$728.7 million and EPS of C$0.66 in Q3 2025 to C$1.0b and C$1.20 in Q3 2026, with trailing twelve month revenue at C$3.4b and EPS of C$3.03 setting the backdrop for how investors read these numbers. With trailing net profit margins now higher than a year ago, the...
NYSE:NABL
NYSE:NABLSoftware

Is N-able (NABL) Offering An Opportunity After Its 19.7% One Year Share Price Decline

If you are wondering whether N-able's share price around US$7.31 actually reflects its underlying worth, you are not alone. This article is built to help you size that up clearly. Over the past week the stock is roughly flat at a 0.1% return, but that sits against a 4.2% decline over 30 days and a 19.7% decline over the past year, which can change how investors view both its potential and its risks. Recent coverage has focused on how N-able is positioned within the broader software and IT...
NYSE:RPC
NYSE:RPCCapital Markets

Is P10 (PX) Pricing Justified After Three-Year Share Price Decline?

If you have been wondering whether P10 is priced attractively right now, you are not alone. Many investors are asking the same question about what they are really paying for with this stock. P10 shares last closed at US$10.33, with recent returns of 4.4% over the past week, 1.2% over the past month, 4.4% year to date, and a 17.6% decline over the past year and 7.6% decline over three years. Recent market attention on P10 has been shaped by ongoing discussion around its role in the...
NasdaqGM:IMRX
NasdaqGM:IMRXBiotechs

Why Immuneering (IMRX) Is Down 29.7% After Phase 2a Pancreatic Data Versus Historical Benchmarks And Phase 3 Plan

Immuneering Corporation recently reported updated Phase 2a data showing encouraging overall survival, response, and safety outcomes for its atebimetinib plus modified gemcitabine/nab-paclitaxel regimen in previously untreated pancreatic cancer patients, and confirmed plans to begin a pivotal Phase 3 trial in mid-2026. A key nuance is that the reported survival benefit is based on comparisons to historical MPACT trial benchmarks rather than a head-to-head control arm, which may influence how...
NYSE:BLX
NYSE:BLXDiversified Financial

Is Banco Latinoamericano De Comercio Exterior (BLX) Still Priced Attractively After Its Recent Run?

If you are wondering whether Banco Latinoamericano de Comercio Exterior S. A is still attractively priced after its recent run, this article will walk through what the current share price might imply about value. The stock closed at US$43.45, with returns of 26.7% over the past year, even though the last 7 days and 30 days saw returns of a 0.8% decline and a 3.5% decline respectively. Recent interest around BLX has largely centered on its role as a specialist trade finance bank for Latin...
TASE:POLI
TASE:POLIBanks

Assessing Bank Hapoalim (TASE:POLI) Valuation After New USD Senior Unsecured Notes Offering

Bank Hapoalim B.M (TASE:POLI) has launched a USD benchmark offering of senior unsecured notes, which will be issued in two tranches and listed on the Tel Aviv Stock Exchange, attracting major global underwriting banks. See our latest analysis for Bank Hapoalim B.M. That bond issue lands at a time when the share price has been firming, with a 2.2% 1 day share price return, 17% 90 day share price return and a 77.6% 1 year total shareholder return suggesting momentum has been building over both...
NYSE:TFX
NYSE:TFXMedical Equipment

Teleflex (TFX) Valuation After 2025 Outlook Cut And CEO Change

What triggered the latest Teleflex stock reaction Teleflex (TFX) shares moved after the company cut its 2025 revenue outlook and announced leadership changes, including the departure of long standing CEO Liam Kelly and the appointment of interim CEO Stuart Randle. See our latest analysis for Teleflex. Those guidance cuts and leadership changes came after a weaker patch, with a 30 day share price return of 11.35% and a 1 year total shareholder return decline of 34.67%, showing momentum has...
NasdaqCM:LQDA
NasdaqCM:LQDAPharmaceuticals

Is It Too Late To Reassess Liquidia (LQDA) After Its Sharp Share Price Surge?

If you are wondering whether Liquidia's share price still offers value after a strong run, the starting point is understanding how its current market price lines up with different ways of estimating worth. Liquidia's stock closed at US$35.86, with returns of 14.2% over the past week, 9.7% over the past month and 14.2% year to date, while the 1 year return sits at 194.2% and the 3 year return is very large. Recent attention on Liquidia has centered on its position in pharmaceuticals and...
NasdaqGS:PCRX
NasdaqGS:PCRXPharmaceuticals

Assessing Pacira BioSciences (PCRX) Valuation After Record EXPAREL Quarter Buybacks And Activist Pressure

What triggered the latest move in Pacira BioSciences? Pacira BioSciences (PCRX) has drawn attention after reporting record EXPAREL sales with 7% volume growth in what it called its strongest fourth quarter in three years, along with a completed fourth quarter share repurchase and fresh activist pressure on the board. See our latest analysis for Pacira BioSciences. Despite record EXPAREL sales and a completed buyback that retired 13.28% of shares under the May 2025 program, Pacira BioSciences’...
CPSE:PNDORA
CPSE:PNDORALuxury

Is Pandora (CPSE:PNDORA) Now Attractively Priced After A 55% One Year Share Price Slide?

You may be wondering if Pandora is starting to look like value after a tough run, or if the risks still outweigh the potential reward for you as a shareholder or watchlist follower. The stock last closed at DKK 588.4, after a 15.4% decline over 7 days, a 16.8% decline over 30 days, a 15.4% decline year to date and a 55.0% decline over the past year, while the 3 year and 5 year returns sit at 10.7% and 6.8% respectively. Recent price moves have come alongside ongoing market attention on...
TSX:ALS
TSX:ALSMetals and Mining

A Look At Altius Minerals (TSX:ALS) Valuation After Recent Project Generation And Royalty Portfolio Updates

Altius Minerals (TSX:ALS) has drawn fresh attention after updating investors on several Project Generation moves, including funding private explorer Centauri Minerals and increasing its equity position in Perseverance Metals. See our latest analysis for Altius Minerals. Those Project Generation updates are landing against a strong run in the stock, with Altius Minerals’ share price at CA$43.81 after a 35.38% 90 day share price return and a 58.84% 1 year total shareholder return, which...
ENXTAM:FLOW
ENXTAM:FLOWCapital Markets

Assessing Flow Traders (ENXTAM:FLOW) Valuation After Stronger Q4 Update And Recent Share Price Rebound

Flow Traders (ENXTAM:FLOW) recently released its 4Q 2025 pre-close call script, noting higher trading volumes and volatility across most asset classes and regions, with a positive impact on fourth quarter performance compared with the third quarter. See our latest analysis for Flow Traders. The latest pre close update comes after a period where momentum has been picking up, with a 1 month share price return of 9.30% and a 1 year total shareholder return of 13.28%. The 3 year total shareholder...
NasdaqGS:QURE
NasdaqGS:QUREBiotechs

Is It Time To Reassess uniQure (QURE) After 83% One Year Share Price Gain?

If you are wondering whether uniQure's share price lines up with its underlying value, this article walks through the key numbers so you can judge for yourself. Over the past year, uniQure's stock has returned 82.8%, with shorter term moves of 8.3% over 7 days and 25.7% over 30 days from a last close of US$25.32. These shifts can affect how investors think about both upside and risk. Recent news around uniQure has focused on its gene therapy pipeline and partnerships, which helps explain why...
NYSE:EIX
NYSE:EIXElectric Utilities

Is Edison International (EIX) Pricing Reflect Grid Reliability And Wildfire Risk Concerns?

If you are wondering whether Edison International is offering fair value right now, it helps to step back and line up what the recent share performance and fundamentals are actually telling you. The stock last closed at US$60.99, with returns of 0.1% over 7 days, 6.1% over 30 days, 0.1% year to date, 0.3% decline over 1 year, 3.5% over 3 years, and 24.7% over 5 years. Taken together, these figures give a mixed picture of how the market has been pricing the company over different time...